Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Assets (2019 - 2025)

Biodesix (BDSX) has disclosed Assets for 7 consecutive years, with $87.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets fell 10.04% year-over-year to $87.5 million, compared with a TTM value of $87.5 million through Dec 2025, down 10.04%, and an annual FY2025 reading of $87.5 million, down 10.04% over the prior year.
  • Assets was $87.5 million for Q4 2025 at Biodesix, down from $88.7 million in the prior quarter.
  • Across five years, Assets topped out at $115.8 million in Q2 2024 and bottomed at $61.7 million in Q1 2022.
  • Average Assets over 5 years is $88.7 million, with a median of $87.6 million recorded in 2025.
  • The sharpest move saw Assets surged 93.35% in 2021, then plummeted 46.62% in 2022.
  • Year by year, Assets stood at $76.1 million in 2021, then rose by 22.09% to $92.9 million in 2022, then increased by 6.66% to $99.1 million in 2023, then decreased by 1.87% to $97.2 million in 2024, then fell by 10.04% to $87.5 million in 2025.
  • Business Quant data shows Assets for BDSX at $87.5 million in Q4 2025, $88.7 million in Q3 2025, and $87.7 million in Q2 2025.